RAHWAY, N.J.--(BUSINESS WIRE)--$MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive results from the Phase 3 ...
A first-in-human Phase I study of SHR-4849 (IDE849), a Delta-like ligand 3 (DLL3)-directed antibody-drug conjugate (ADC), demonstrated manageable safety and early signs of anti-tumor activity in ...
A novel antibody-drug conjugate (ADC), iza-bren (BL-B01D1), demonstrates encouraging safety and efficacy results in previously treated patients with EGFR-mutated non-small cell lung cancer (NSCLC), ...
OBI-902 is the first ADC utilizing OBI’s proprietary GlycOBI® ADC enabling technology for evaluation of safety and efficacy in Cancer. TAIPEI, Taiwan, Sept. 02, 2025 (GLOBE NEWSWIRE) -- OBI Pharma, a ...
Please provide your email address to receive an email when new articles are posted on . A novel assay may help direct antibody-drug conjugate therapy through measurements of HER2 and TROP2. Most ...
The first-in-class antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) demonstrated promising efficacy and high response rates for patients with blastic plasmacytoid dendric cell neoplasm (BPDCN), ...
Antibody-drug conjugates (ADCs) are transforming targeted cancer therapy, with innovations in conjugation chemistry and payload-linker technologies driving improvements in efficacy, stability, and ...
Researchers have developed a novel antibody-toxin conjugate (ATC) designed to stimulate immune-mediated eradication of tumors. According to preclinical results, the approach combined the benefits of ...
ABBV-154, an antibody-drug conjugate comprising adalimumab conjugated to a proprietary glucocorticoid receptor modulator, shows potential for extending flare-free periods in patients with ...
GSK’227 is a novel antibody-drug conjugate composed of a fully human anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor payload. The Food and Drug Administration (FDA) has ...
This trial is assessing CBX-12 as a potential treatment for ovarian cancer, with additional studies to be conducted in other solid tumor types. The first patient has been dosed in a trial assessing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback